$VKTX
Viking Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022016129 Filed on April 27, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.690M $2.690M $2.220M
YoY Change 37.17% -9.12% -8.26%
% of Gross Profit
Research & Development $12.56M $11.54M $9.050M
YoY Change 8.8% 44.43% 40.31%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $16.25M $14.23M $11.27M
YoY Change 14.18% 29.96% 27.06%
Operating Profit -$16.25M
YoY Change
Interest Expense $154.0K $239.0K $320.0K
YoY Change -35.56% -81.03% -77.46%
% of Operating Profit
Other Income/Expense, Net $142.0K $218.0K
YoY Change -34.86%
Pretax Income -$16.10M -$14.01M -$10.95M
YoY Change 14.94% 44.58% 46.98%
Income Tax
% Of Pretax Income
Net Earnings -$16.10M -$14.01M -$10.95M
YoY Change 14.94% 44.63% 46.98%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$208.0K -$186.9K -$150.2K
COMMON SHARES
Basic Shares Outstanding 78.36M
Diluted Shares Outstanding 77.41M

Balance Sheet

Concept 2022 Q1 2021 Q1 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $184.9M $241.7M $248.4M
YoY Change -23.5% -10.2% -9.89%
Cash & Equivalents $12.45M $16.81M $29.12M
Short-Term Investments $172.4M $224.9M $219.3M
Other Short-Term Assets $8.400M $8.200M $7.700M
YoY Change 2.44% 12.33% -2.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $193.3M $249.9M $256.1M
YoY Change -22.65% -9.59% -9.67%
LONG-TERM ASSETS
Property, Plant & Equipment $1.632M $200.0K $300.0K
YoY Change 716.0% -60.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $97.00K $0.00 $100.0K
YoY Change -100.0% -50.0%
Total Long-Term Assets $1.729M $239.0K $400.0K
YoY Change 623.43% -65.86% -47.02%
TOTAL ASSETS
Total Short-Term Assets $193.3M $249.9M $256.1M
Total Long-Term Assets $1.729M $239.0K $400.0K
Total Assets $195.0M $250.1M $256.5M
YoY Change -22.03% -9.73% -9.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.119M $4.848M $4.000M
YoY Change -35.66% 56.39% 64.54%
Accrued Expenses $8.149M $8.100M $8.100M
YoY Change 0.6% 50.0% 88.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.27M $12.92M $12.13M
YoY Change -12.76% 51.21% 78.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.490M $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $1.490M $0.00 $29.00K
YoY Change -100.0% -91.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.27M $12.92M $12.13M
Total Long-Term Liabilities $1.490M $0.00 $29.00K
Total Liabilities $12.76M $12.92M $12.16M
YoY Change -1.22% 46.42% 70.35%
SHAREHOLDERS EQUITY
Retained Earnings -$182.2M -$168.2M
YoY Change 31.66% 30.69%
Common Stock $419.5M $412.6M
YoY Change 2.96% 1.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $182.3M $237.2M $244.3M
YoY Change
Total Liabilities & Shareholders Equity $195.0M $250.1M $256.5M
YoY Change -22.03% -9.73% -9.76%

Cashflow Statement

Concept 2022 Q1 2021 Q1 2020 Q4
OPERATING ACTIVITIES
Net Income -$16.10M -$14.01M -$10.95M
YoY Change 14.94% 44.63% 46.98%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.53M -$10.88M -$5.490M
YoY Change -3.18% 152.81% -53.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.619M -$6.630M $30.27M
YoY Change -124.42% -159.46% -373.69%
Cash From Investing Activities $1.619M -$6.627M $30.27M
YoY Change -124.43% -159.42% -373.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.121M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.006M 5.191M 460.0K
YoY Change -196.44% 15630.3% 100.0%
NET CHANGE
Cash From Operating Activities -10.53M -10.88M -5.490M
Cash From Investing Activities 1.619M -6.627M 30.27M
Cash From Financing Activities -5.006M 5.191M 460.0K
Net Change In Cash -13.92M -12.31M 25.24M
YoY Change 13.04% -278.88% -211.83%
FREE CASH FLOW
Cash From Operating Activities -$10.53M -$10.88M -$5.490M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M29D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M9D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y25D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M24D
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
2357000
CY2022Q1 vktx Shares Withheld Related To Employee Tax Withholding Value
SharesWithheldRelatedToEmployeeTaxWithholdingValue
499000
CY2022Q1 vktx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
614000
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
5121000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-893000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
154000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
239000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
218000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
31000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
201884000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
31000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16103000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
182270000
CY2021Q1 vktx Receivable From Exercise Of Warrants
ReceivableFromExerciseOfWarrants
173000
CY2021Q1 vktx Shares Withheld Related To Employee Tax Withholding Value
SharesWithheldRelatedToEmployeeTaxWithholdingValue
473000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
156000
CY2021Q1 vktx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
5679000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14010000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16103000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-14010000
CY2022Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-670000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1138000
CY2022Q1 vktx Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
12000
CY2021Q1 vktx Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
21000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2357000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1577000
CY2022Q1 vktx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
77000
CY2021Q1 vktx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
72000
CY2022Q1 vktx Operating Leases Interest Expense
OperatingLeasesInterestExpense
4000
CY2021Q1 vktx Operating Leases Interest Expense
OperatingLeasesInterestExpense
5000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
266000
CY2022Q1 vktx Change In Accrued Interest Relating To Marketable Securities Held As Investments
ChangeInAccruedInterestRelatingToMarketableSecuritiesHeldAsInvestments
-105000
CY2021Q1 vktx Change In Accrued Interest Relating To Marketable Securities Held As Investments
ChangeInAccruedInterestRelatingToMarketableSecuritiesHeldAsInvestments
166000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1707000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
860000
CY2022Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
694000
CY2021Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-22000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-76000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-85000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10530000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10876000
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
30682000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
48676000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
32301000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
42049000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1619000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6627000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
473000
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5121000
CY2022Q1 vktx Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan
ProceedsFromWarrantAndOptionExercisesAndStockIssuanceUnderEmployeeStockPurchasePlan
614000
CY2021Q1 vktx Proceeds From Warrant And Option Exercises And Stock Issuance Under Employee Stock Purchase Plan
ProceedsFromWarrantAndOptionExercisesAndStockIssuanceUnderEmployeeStockPurchasePlan
5664000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5006000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5191000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13917000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12312000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29117000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12454000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16805000
CY2022Q1 vktx Unpaid Deferred Initial Public Offering And Other Financing Costs
UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts
50000
CY2021Q1 vktx Unpaid Deferred Initial Public Offering And Other Financing Costs
UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts
50000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1664000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
499000
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates made in preparing these consolidated financial statements relate to accounting for an operating lease and certain commitments. Actual results could differ from those estimates.</p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p>
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
31000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16103000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14010000
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
77596236
CY2021Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
74965522
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77413141
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74782427
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7041371
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6840964
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
173887000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1444000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
172445000
CY2022Q1 vktx Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
1
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
175732000
CY2021Q4 vktx Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
3
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
75
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
178605000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24612000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
1000000
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
0.01
CY2014Q1 vktx Number Of Tranches
NumberOfTranches
2
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
168000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
633810
CY2015Q2 vktx Shares Repurchase Price Per Share
SharesRepurchasePricePerShare
0.00001
CY2015Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
366190
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
62000
CY2020 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2021 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2018 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2019 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2022Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2021Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2357000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1577000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2357000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1577000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.61
CY2022Q1 vktx Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
5000
CY2022Q1 vktx Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
6.61
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.46
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1373000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.26
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1373000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
156000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.53
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8731
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0150
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7500000
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7500000
CY2016Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.25
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2016Q2 us-gaap Share Price
SharePrice
0.01
CY2021Q2 vktx Class Of Warrants Or Rights Expired
ClassOfWarrantsOrRightsExpired
29101
CY2021Q4 vktx Operating Lease Option To Extend Term
OperatingLeaseOptionToExtendTerm
P5Y
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0300
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
81000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
77000

Files In Submission

Name View Source Status
0001564590-22-016129-index-headers.html Edgar Link pending
0001564590-22-016129-index.html Edgar Link pending
0001564590-22-016129.txt Edgar Link pending
0001564590-22-016129-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vktx-10q_20220331.htm Edgar Link pending
vktx-10q_20220331_htm.xml Edgar Link completed
vktx-20220331.xsd Edgar Link pending
vktx-20220331_cal.xml Edgar Link unprocessable
vktx-20220331_def.xml Edgar Link unprocessable
vktx-20220331_lab.xml Edgar Link unprocessable
vktx-20220331_pre.xml Edgar Link unprocessable
vktx-ex311_6.htm Edgar Link pending
vktx-ex312_7.htm Edgar Link pending
vktx-ex321_8.htm Edgar Link pending